Neurotrophic and Inflammatory Biomarkers in the Cerebrospinal Fluid of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder
Clinical and Experimental Neuroimmunology · 2026-11 · 17 (4)
DOI: 10.1111/cen3.70095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Neuroimmunology, online erschienen am 20.11.2026. Verfasst von Hayriye Soytürk und 5 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) are inflammatory demyelinating diseases with distinct immunopathological mechanisms. The relationship between neurotrophic signaling and inflammation in these disorders remains incompletely understood.
Objective
To compare cerebrospinal fluid (CSF) neurotrophic and inflammatory biomarkers in MS, NMOSD, and non‐inflammatory controls and to investigate their interrelationships: Methods This retrospective case–control study included 14 patients with MS, six with NMOSD, and seven controls. CSF concentrations of glial cell line–derived neurotrophic factor (GDNF), GDNF family receptor alpha‐1 (GFRα1), nerve growth factor (NGF), interleukin‐1 beta (IL‐1β), and interleukin‐22 (IL‐22) were measured using enzyme‐linked immunosorbent assays. The GFRα1/GDNF ratio was calculated as an exploratory indicator of receptor–ligand balance. Group differences and biomarker correlations were evaluated using non‐parametric analyses.
Results
GFRα1 concentrations differed significantly among the groups ( p = 0.019) and were higher in MS than in controls (adjusted p = 0.016). The GFRα1/GDNF ratio was elevated in both NMOSD (adjusted p = 0.001) and MS (adjusted p = 0.017) compared with controls. GDNF, NGF, IL‐1β, and IL‐22 concentrations did not differ significantly among the groups. Within the combined patient cohort, GDNF correlated positively with GFRα1, IL‐1β, IL‐22, and NGF (all p ≤ 0.009) and negatively with the GFRα1/GDNF ratio ( ρ = −0.809, p < 0.001). The IgG index was significantly higher in MS than in NMOSD and controls ( p < 0.001).
Conclusion
Altered GFRα1 expression and receptor–ligand balance may reflect coordinated inflammatory–neurotrophic responses in MS and NMOSD. The GFRα1/GDNF ratio warrants validation as an exploratory CSF biomarker.
Zitieren
APA
Soytürk, H., Kılıç, Ü., Atasever, Ü., Bakkal, P. Ş., Önal, C., & Türkoğlu, Ş. A. (2026). Neurotrophic and Inflammatory Biomarkers in the Cerebrospinal Fluid of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Clinical and Experimental Neuroimmunology, 17(4). https://doi.org/10.1111/cen3.70095
Vancouver
Soytürk H, Kılıç Ü, Atasever Ü, Bakkal PŞ, Önal C, Türkoğlu ŞA. Neurotrophic and Inflammatory Biomarkers in the Cerebrospinal Fluid of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. Clinical and Experimental Neuroimmunology. 2026;17(4). doi:10.1111/cen3.70095
BibTeX
@article{Soytrk2026,
author = {Soytürk, Hayriye and Kılıç, Ümit and Atasever, Ümit and Bakkal, Petek Şarlı and Önal, Cansu and Türkoğlu, Şule Aydın},
title = {Neurotrophic and Inflammatory Biomarkers in the Cerebrospinal Fluid of Patients With Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder},
journal = {Clinical and Experimental Neuroimmunology},
year = {2026},
volume = {17},
number = {4},
doi = {10.1111/cen3.70095}
}
EUVIMED